Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Next-generation anti-BCMA CAR T shows promise for RRMM

Key clinical point: CT053, a chimeric antigen receptor T-cell therapy, demonstrated efficacy and tolerability in patients with relapsed/refractory multiple myeloma.

Major finding: CT053 produced an objective response rate of 87.5% and a complete response rate of 79.2%. All patients experienced grade 3 or higher adverse events, but none developed grade 3 or higher cytokine-release syndrome.

Study details: A phase 1 trial of 24 patients with multiple myeloma.

Disclosures: The trial was sponsored by Xinhua Hospital/Shanghai Jiao Tong University School of Medicine, First Affiliated Hospital of Zhejiang University, and First Affiliated Hospital of Wenzhou Medical University in collaboration with Carsgen Therapeutics. Dr. Hao did not disclose any conflicts of interest.


Hao S et al. IMW 2019, Abstract OAB-082.